Carbon dioxide-to-fuel technology developer Algenol has secured another $25m from BioFields, the biofuel producer that invested $40m in the company last year.

Queensland life sciences spin-out Vaxxas secures A$25m ($20m) for needleless injection technologies.

The genome sequencing technology developer raised the funding from backers including the venture capital arms of Mitsubishi and Mizuho.

G1 Therapeutics has completed a MedImmune-backed series B round to fund development of its drug protecting bone marrow in cancer patients.

Chapel Hill spin-out G1 Therapeutics lands $33m series B for less toxic oncology treatments.

Video conferencing service Zoom has secured $30m in a series C round featuring returning investor Qualcomm, and which lifted its overall funding to more than to $45m.

Lysosomal has raised $20m in a round backed by pharmaceutical firms Roche, Eli Lilly and Sanofi, all of which also contributed to its $4.8m seed round.

Offshore wind turbine developer 2-B has raised a $30m venture round backed by Shell, Rabobank and a host of government-backed participants.